This form does not yet contain any fields.

    Entries in laser therapy (4)


    PBM and Cancer - What is the Truth?

    Results: Although there are a few articles suggesting that PBM therapy can be detrimental in animal models of tumors, there are also many articles that suggest the opposite and that light can directly damage the tumor, can potentiate other cancer therapies, and can stimulate the host immune system. Moreover, there are two clinical trials showing increased survival in cancer patients who received PBM therapy. 

    Conclusions: PBM therapy may have benefits in cancer patients and should be further investigated.

    Read the full article here.


    PBM? Do you have any scientific references for your claims?

    Not too seldom, non-believers in PBM will ask for references, having difficulties in accepting what you say. Providing such references can take time and you may not be too used to collect them or to know where to find them. Below, then, is a brief selection of recent studies. 

    Here are the studies.


    The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: A randomized, sham-controlled clinical trial


    Background. Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer therapy with few efficacious treatments.
    Methods. We enrolled 70 patients with CIPN in a randomized, double-blinded, sham-controlled, cross-over trial to determine if photobiomodulation (PBM) ± physiotherapy reduced the symptoms of neuropathy compared to sham treatment. At the conclusion of follow-up, sham-arm patients could cross-over into a third arm combining PBM and physiotherapy to determine if multimodal treatment had additive effects. Treatment included 30 minute sessions 3-times weekly for 6 weeks using either PBM or sham therapy. Neuropathy was assessed using the modified total neuropathy score (mTNS) at initiation and 4, 8, and 16 weeks after initiating treatment.
    Results. Sham-treated patients experienced no significant change in mTNS scores at any point during the primary analysis. PBM patients experienced significant reduction inmTNS scores at all time points.Mean changes in mTNS score (and corresponding percent drop from baseline) for sham and PBM-group patients respectively were −0.1 (−0.7%) and −4.2 (−32.4%) at 4 weeks (p b 0.001), 0.2 (0.0%) and −6.8 (−52.6%) at 8 weeks (p b 0.001), and 0.0 (0.1%) and −5.0 (−38.8%) at 16 weeks (p b 0.001). Patients who crossed over into the PBM/PT-group experienced similar results to those treated primarily; changes in mTNS score from baseline were −5.5 (−40.6%) 4 weeks (p b 0.001), −6.9 (−50.9%) at 8 weeks (p b 0.001), and −4.9 (−35.9%) at
    16 weeks (p b 0.001). The addition of physiotherapy did not improve outcomes over PBM alone.

    Conclusion and relevance. Among patients with CIPN, PBM produced significant reduction in neuropathy symptoms.

    The photobiomodulation in this study was delivered using a K-1200 class 4 therapy laser from K-Laser USA.

    The full study can be accessed through Gynecologic Oncology online.


    The mechanistic basis for photobiomodulation therapy of neuropathic pain by near infrared laser light.

    Laser therapy (photobiomodulation) can help patients suffering from neuropathy.

    Using in vivo and in vitro experimental models, this study determined the mechanistic basis of photobiomodulation therapy (PBMT) for the treatment of neuropathic pain using a high irradiance.

    Click here to read the abstract on PubMed.